Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure

Yanai, Hidekatsu

doi:10.14740/jem426w

Cited by 3 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chronic effects of SGLT2i for the prevention of heart failure include an improvement in myocardial energetics, reduction of albuminuria, suppression of eGFR decline, reduced sympathetic overactivity, and anti-atherosclerotic effects [ 22 , 25 , 26 ]. SGLT2i may induce relative glucose deficiency, and may then trigger increased lipolysis and fatty acids (FA) oxidation, which increase hepatic ketone bodies’ production [ 27 ].…”

Section: Cardiovascular Protective Effects Of Sglt2imentioning

confidence: 99%

Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors

Yanai

Hakoshima

Adachi

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

Sodium glucose cotransporter 2 inhibitors (SGLT2i) block the reabsorption of glucose by inhibiting SGLT2, thus improving glucose control by promoting the renal excretion of glucose, without requiring insulin secretion. This pharmacological property of SGLT2i reduces body weight and improves insulin resistance in diabetic patients. Such beneficial metabolic changes caused by SGLT2i are expected to be useful not only for glucose metabolism, but also for the protection for various organs. Recent randomized controlled trials (RCTs) on cardiovascular diseases (EMPA-REG OUTCOME trial and CANVAS program) showed that SGLT2i prevented cardiovascular death and the development of heart failure. RCTs on renal events (EMPA-REG OUTCOME trial, CANVAS program, and CREDENCE trial) showed that SGLT2i suppressed the progression of kidney disease. Furthermore, SGLT2i effectively lowered the liver fat content, and our study demonstrated that SGLT2i reduced the degree of hepatic fibrosis in patients at high-risk of hepatic fibrosis. Such promising properties of SGLT2i for cardiovascular, renal, and hepatic protection provide us the chance to think about the underlying mechanisms for SGLT2i-induced improvement of multiple organs. SGLT2i have various mechanisms for organ protection beyond glucose-lowering effects, such as an increase in fatty acids utilization for hepatic protection, osmotic diuresis for cardiac protection, an improvement of insulin resistance for anti-atherogenesis, and an improvement of tubuloglomerular feedback for renal protection.

show abstract

Section: Cardiovascular Protective Effects Of Sglt2imentioning

confidence: 99%

Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors

Yanai

Hakoshima

Adachi

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…Chronic effects of SGLT2i for prevention of heart failure include improvement of myocardial energetics, reduction of al-buminuria, suppression of eGFR decline, reduced sympathetic overactivity and anti-atherosclerotic effects (Fig. 1) [4,8,9].…”

Section: To the Editormentioning

confidence: 99%

Acute Effects of Preventing Heart Failure by Sodium-Glucose Cotransporter 2 Inhibitors

Yanai

2021

Cardiol Res

Self Cite

View full text Add to dashboard Cite

“…Further, the CVD-REAL study, the large multinational study, presented that treatment with SGLT2i was associated with a lower risk of hospitalization for heart failure and death as compared with other glucose lowering drugs [ 7 ]. Prevention of development of heart failure by SGLT2i has been attracting a lot of attention [ 8 ].…”

Section: To the Editormentioning

confidence: 99%